NUVL News and Press, Nuvalent Inc. From 10/13/23

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC PR Newswire Encouraging preliminary signs of activity observed in heavily pre-treated patients with ALK-positive NSCLC, i...

2023-10-09 10:48:57 ET More on Nuvalent Nuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On Dip Nuvalent surges on Phase 1 data for lung cancer therapy Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent For...

2023-10-05 19:13:22 ET Shares of Nuvalent (NASDAQ: NUVL) are up 35.3% this week as of Thursday's close, according to data provided by S&P Global Market Intelligence , after the company announced favorable data in a trial for a key lung cancer drug. In a press release Wed...

2023-10-05 11:00:43 ET Summary Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is focused on developing targeted therapies for cancer patients, with its lead drug candidates showing...

2023-10-04 16:13:47 ET Shares of Nuvalent (NASDAQ: NUVL) were up more than 27% as of 3:30 p.m. ET on Wednesday after the company reported preliminary phase 1/2 trial data for a therapy to treat advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors. The stoc...

2023-10-04 13:55:53 ET Gainers: Vivos Therapeutics ( VVOS ) +111% . Nuvalent ( NUVL ) +30% . Spectral AI ( MDAI ) +27% . Gaucho Group Holdings ( VINO ) +25% . Gritstone Bio ( GRTS ) +19% . BioXcel Therapeutics ( BTAI ) ...

2023-10-04 12:58:46 ET More on Nuvalent Seeking Alpha’s Quant Rating on Nuvalent Historical earnings data for Nuvalent Financial information for Nuvalent For further details see: Nuvalent surges on Phase 1 data for lung cancer therapy

Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile PR Newswire Updated preliminary data to be presented at the 35 th AACR-NCI...

Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium PR Newswire Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent,...

Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors PR Newswire Alignment with US Food and Drug Administration on a Recommended Phase 2 Dose for NVL-520 of 100 mg daily CAMBRIDGE, Mass. , ...